Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Oncology
Autophagosome-Based Strategy To Monitor Apparent Tumor-Specific Cd8 T Cells In Patients With Prostate Cancer., Rieneke Van De Ven, Traci L Hilton, Hong-Ming Hu, Christopher J Dubay, Daniel Haley, Christopher Paustian, Sachin Puri, Walter Urba, Brendan Curti, Sandra Aung, Bernard A Fox
Autophagosome-Based Strategy To Monitor Apparent Tumor-Specific Cd8 T Cells In Patients With Prostate Cancer., Rieneke Van De Ven, Traci L Hilton, Hong-Ming Hu, Christopher J Dubay, Daniel Haley, Christopher Paustian, Sachin Puri, Walter Urba, Brendan Curti, Sandra Aung, Bernard A Fox
Articles, Abstracts, and Reports
The immune system plays an essential role in eradicating cancer in concert with various treatment modalities. In the absence of autologous tumor material, no standardized method exists to assess T cell responses against the many antigens that may serve as cancer rejection antigens. Thus, development of methods to screen for therapy-induced anti-tumor responses is a high priority that could help tailor therapy. Here we tested whether a tumor-derived antigen source called DRibbles®, which contain a pool of defective ribosomal products (DRiPs), long-lived and short-lived proteins (SLiPs) and danger-associated molecular patterns (DAMPs), can be used to identify tumor-associated antigen (TAA)-specific responses …
Effectiveness Of Subcutaneously Administered Leuprolide Acetate To Achieve Low Nadir Testosterone In Prostate Cancer Patients., Christopher M Pieczonka, Przemyslaw Twardowski, Joseph Renzulli, Jason Hafron, Deborah M Boldt-Houle, Stuart Atkinson, Scott Eggener
Effectiveness Of Subcutaneously Administered Leuprolide Acetate To Achieve Low Nadir Testosterone In Prostate Cancer Patients., Christopher M Pieczonka, Przemyslaw Twardowski, Joseph Renzulli, Jason Hafron, Deborah M Boldt-Houle, Stuart Atkinson, Scott Eggener
Articles, Abstracts, and Reports
Evidence suggests lower nadir testosterone levels during the first year of androgen deprivation therapy improve advanced prostate cancer clinical outcomes. We evaluated pivotal trials for subcutaneously administered leuprolide acetate (1-, 3-, 4-, and 6-month doses) to determine nadir testosterone levels. Pooled analysis showed 99%, 97%, and 91% of patients reached nadir testosterone ≤20, ≤10, and ≤5 ng/dL respectively (median ≤3 ng/dL). Across all available categories, $88% of patients reached nadir testosterone ≤5 ng/dL, and